Get notified when MYGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Conflict of Interest (new) — Underwriters' affiliates are lenders to the company and will receive 5% or more of the net proceeds, creating a conflict of interest under FINRA Rule 5121.
- Securities Class Action Settlement (new) — The company has agreed to a $77.5 million settlement of a securities class action, with final court approval still pending.
Myriad Genetics prices 6.47M-share offering at $17.00, raising $110.0M gross to repay debt and settle class action
Filed November 13, 2023 · ~1 min read
Key Changes
-
high
Myriad Genetics is offering 6,470,588 shares at $17.00 per share, for gross proceeds of $110.0M; net proceeds to the company are approximately $102.2M.
The Offering verify on EDGAR → -
high
The company will use $40.0M of net proceeds to repay all outstanding ABL Facility loans and $57.5M to pay the remaining securities class action settlement, with the rest for working capital.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $15.39 per share ($15.24 if underwriters' option fully exercised), as the offer price far exceeds the as-adjusted net tangible book value of $1.61 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade MYGN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify